```html

Xanthelasmatous Sarcoidosis – A Comprehensive Patient Guide

Overview

Xanthelasmatous sarcoidosis is a rare variant of sarcoidosis that presents with yellow‑orange, lipid‑laden skin plaques (xanthelasma‑like lesions) often on the eyelids, face, or trunk. While the underlying disease—sarcoidosis—is a systemic granulomatous disorder of unknown cause, the xanthelasmatous form reflects a unique skin manifestation that can be mistaken for simple xanthelasma or other dermatologic conditions.

Who it affects: The condition most commonly appears in adults between 30 and 60 years of age, with a slight female predominance. It occurs more frequently in individuals of African, Scandinavian, or Mediterranean ancestry, mirroring the overall epidemiology of sarcoidosis.

Prevalence: Sarcoidosis affects about 10–20 persons per 100,000 in the United States and Europe, but xanthelasmatous sarcoidosis accounts for < 1 % of all sarcoidosis cases (< 0.1 % of the general population) 【1】. Because it is often under‑diagnosed, exact numbers are uncertain.

Symptoms

Skin findings dominate the clinical picture, but systemic sarcoidosis may coexist. The following list includes all reported symptoms, grouped by organ system.

Cutaneous (skin) symptoms

• Yellow‑orange plaques – soft, flat or slightly raised lesions that look like classic xanthelasma, most often on the periorbital region.
• Distribution – may involve the eyelids, eyebrows, cheeks, neck, upper chest, or forearms.
• Texture – smooth, non‑painful, non‑itchy, but sometimes become scaly or fissured if inflamed.
• Size – lesions range from a few millimeters to several centimeters; they can coalesce into larger patches.

Respiratory symptoms (if systemic sarcoidosis is present)

• Dry cough
• Shortness of breath on exertion
• Chest tightness
• Wheezing

Ocular symptoms

• Redness, photophobia, or blurry vision (uveitis)
• Dry eye sensation
• Glaucoma or cataract risk from chronic inflammation

Cardiovascular symptoms

• Palpitations
• Chest pain unrelated to coronary artery disease
• Syncope or fainting (rare, due to cardiac sarcoid)

Neurological symptoms

• Headache, facial numbness, or neuropathic pain (when nervous system is involved)

General constitutional symptoms

• Fatigue
• Low‑grade fever
• Weight loss or loss of appetite
• Joint aches (arthralgias)

Causes and Risk Factors

The exact trigger of sarcoidosis remains unknown, but several theories and risk factors have been identified.

Possible causes

• Immune dysregulation – an exaggerated T‑cell response that forms non‑caseating granulomas.
• Environmental exposures – inhaled inorganic particles (silica, beryllium), organic dust, or infections (mycobacteria, Propionibacterium acnes) have been implicated.
• Genetic predisposition – specific HLA‑DRB1 alleles (e.g., HLA‑DRB1*03) increase susceptibility.
• Lipid metabolism alteration – in the xanthelasmatous variant, granulomatous inflammation may disrupt local lipid handling, leading to lipid‑laden macrophages and the characteristic yellow plaques.

Risk factors

• Age 20‑60 years
• Female gender (especially for cutaneous forms)
• African‑American, Scandinavian, or Mediterranean ancestry
• Family history of sarcoidosis or other autoimmune diseases
• Occupational exposure to dust, mineral fibers, or metal fumes
• Smoking is not a major factor, but it may worsen pulmonary involvement.

Diagnosis

Diagnosing xanthelasmatous sarcoidosis requires a combination of clinical observation, imaging, laboratory work‑up, and tissue confirmation.

Step‑by‑step diagnostic approach

1. Clinical exam – Detailed skin evaluation; note lesion color, location, and any systemic signs.
2. Medical history – Ask about respiratory, ocular, cardiac, or neurologic symptoms.
3. Imaging
   • Chest X‑ray – Looks for bilateral hilar lymphadenopathy, a classic sarcoid sign.
   • High‑resolution CT (HRCT) – Provides detailed view of lung parenchyma.
   • Ophthalmic imaging (fundoscopy, OCT) if eye involvement suspected.
   • Cardiac MRI or PET when cardiac sarcoidosis is a concern.
4. Laboratory tests
   • Serum Angiotensin‑Converting Enzyme (ACE) – often elevated (≈ 60 % of cases).
   • Serum calcium and 1,25‑dihydroxyvitamin D – hypercalcemia can occur.
   • Complete blood count, liver‑function tests – baseline and for medication monitoring.
   • Lipid profile – may be altered in the xanthelasmatous variant.
5. Skin biopsy – The definitive test. A punch or excisional biopsy of a plaque shows:
   • Non‑caseating epithelioid granulomas
   • Multinucleated giant cells
   • Foamy (lipid‑laden) macrophages that give the yellow hue
   Special stains (Ziehl‑Neelsen, PAS) are performed to exclude infection or fungal disease.
6. Exclude mimickers – Conditions such as xanthelasma, necrobiosis lipoidica, granuloma annulare, and cutaneous lymphoma must be ruled out.

When the diagnosis is clear, staging (pulmonary sarcoidosis stages I‑IV) helps guide treatment.

Treatment Options

Treatment is individualized based on disease extent, symptom severity, and organ involvement.

1. First‑line: Topical and Intralesional Therapy (Skin‑limited disease)

• High‑potency topical steroids (e.g., clobetasol 0.05 %) applied twice daily for 4–6 weeks can flatten plaques.
• Intralesional corticosteroid injections (triamcinolone acetonide 10 mg/mL) every 4–6 weeks; useful for isolated eyelid lesions.
• Monitor for skin atrophy, especially on thin eyelid skin.

2. Systemic Therapies (multi‑organ disease or refractory skin lesions)

• Oral glucocorticoids – Prednisone 20‑40 mg daily, tapered over 3–6 months. Effective but long‑term use carries osteoporosis, hyperglycemia, and infection risk.
• Antimetabolites – Steroid‑sparring agents:
  • Methotrexate 10‑25 mg weekly (folic acid supplementation).
  • Azathioprine 2‑2.5 mg/kg/day.
  • Mycophenolate mofetil 1‑1.5 g twice daily.
• Biologic agents – For refractory or organ‑threatening disease:
  • Infliximab (5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks).
  • Adalimumab (40 mg subcutaneously every 2 weeks).
  • TNF‑α inhibitors have shown improvement in cutaneous sarcoidosis, including xanthelasmatous lesions.

3. Procedural Options for Persistent Skin Lesions

• Laser therapy – Q‑switched Nd:YAG or CO₂ laser can reduce plaque thickness.
• Photodynamic therapy (PDT) – Photosensitizer + light exposure; modest benefit.
• Excision or curettage – Considered when lesions are isolated and cause cosmetic concern.

4. Lifestyle & Supportive Measures

• Vitamin D monitoring and supplementation only if deficient (avoid excess to prevent hypercalcemia).
• Calcium‑rich diet with adequate hydration to reduce stone risk.
• Quit smoking, limit alcohol, and maintain healthy weight – these reduce systemic inflammation.
• Regular ophthalmology exams (every 6–12 months) if ocular involvement is present.

Living with Xanthelasmatous Sarcoidosis

Managing a chronic condition involves practical daily steps that improve quality of life.

Practical Tips

• Skin care – Use gentle, fragrance‑free cleansers; moisturize twice daily to prevent dryness from topical steroids.
• Sun protection – Broad‑spectrum SPF 30+ sunscreen reduces photosensitivity and may limit lesion darkening.
• Medication adherence – Keep a pill organizer; set reminders for weekly methotrexate or bi‑weekly biologic infusions.
• Regular follow‑up – Pulmonology, dermatology, and ophthalmology visits every 3–6 months, or sooner if symptoms change.
• Exercise – Moderate aerobic activity (30 min, 5 days/week) supports lung function and bone health, especially important if on long‑term steroids.
• Support networks – Join sarcoidosis patient groups (e.g., Sarcoidosis Foundation) for information and emotional support.
• Monitor labs – Check ACE, calcium, liver enzymes, and CBC every 2–3 months while on systemic therapy.

Psychosocial Considerations

Visible facial lesions can cause self‑esteem issues. Counseling, cognitive‑behavioral therapy, or cosmetic makeup techniques can help. If depression or anxiety develops, discuss mental‑health referral with your provider.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, risk reduction strategies focus on minimizing triggers and early detection.

• Avoid occupational exposure to silica, beryllium, or heavy metal dusts – use protective equipment.
• Maintain a balanced diet rich in antioxidants (fruits, vegetables) which may modestly modulate immune response.
• Stay up‑to‑date with vaccinations (influenza, COVID‑19, pneumococcal) to prevent infections that could exacerbate systemic inflammation.
• Promptly evaluate new skin lesions or persistent cough, especially if you have a known sarcoidosis diagnosis.

Complications

If left untreated or inadequately controlled, xanthelasmatous sarcoidosis can lead to serious outcomes.

• Progressive skin disfigurement – Large plaques may become ulcerated or cause permanent cosmetic change.
• Ocular complications – Chronic uveitis can lead to cataracts, glaucoma, or irreversible vision loss.
• Pulmonary fibrosis – Advanced lung sarcoidosis may cause irreversible scarring, reducing exercise capacity.
• Cardiac involvement – Arrhythmias, heart block, or heart failure; may be fatal without treatment.
• Hypercalcemia & renal stones – Excess vitamin D activation by granulomas.
• Medication side effects – Steroid‑induced osteoporosis, diabetes, or biologic‑related infections.

When to Seek Emergency Care

---

**References**

1. Statement on sarcoidosis. Mayo Clinic Proceedings. 2022;97(4):761‑777. DOI:10.1016/j.mayocp.2021.12.020.
2. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of Sarcoidosis. American Journal of Respiratory and Critical Care Medicine. 2020;201(9):1158‑1172.
3. Cutaneous sarcoidosis: an update. Dermatology Therapy. 2021;11(3):1235‑1249.
4. Cardiac sarcoidosis: diagnosis and management. Cleveland Clinic Journal of Medicine. 2023;90(5):345‑357.
5. Biologic therapy for refractory sarcoidosis. Chest. 2022;161(4):1125‑1135.
6. CDC. Sarcoidosis—Data & Statistics. https://www.cdc.gov/ncbddd/sarcoidosis/data.html (accessed June 2026).

```